Natera's CLO and Clinical President Both Sold Stock on the Same Day

🔴 Insider Activity Score: 88/100

Daniel Rabinowitz, CLO of Natera, and Solomon Moshkevich, President of Clinical Diagnostics, filed Form 4 disclosures on July 6, 2026 disclosing simultaneous but analytically independent plan-governed distributions: Rabinowitz selling 16,800 shares across a 12-tier execution corridor of $266.33 to $278.78 for approximately $4,574,431 under a December 2025 plan, and Moshkevich selling 3,000 shares across a $267.19 to $274.06 corridor for approximately $818,710 under a November 2024 plan. Combined: 19,800 shares and approximately $5,393,141. Both executives retain combined direct exposure of 296,779 common shares. The same-day appearance is a calendar coincidence — two independent programs executing into the same FDA milestone-driven rally window.

Two Plans, Two Adoption Dates: Analytically Independent

The specific analytical distinction this filing requires is the one this series established in the Seagate three-executive cluster and the DocuSign four-executive same-day distribution: same-day plan executions from different adoption dates are independent programs that happen to share an execution window, not coordinated directional decisions.

Rabinowitz's December 2025 plan and Moshkevich's November 2024 plan — separated by approximately thirteen months in adoption — were designed at different informational moments with different personal financial planning objectives. The November 2024 plan predates the FDA Signatera companion diagnostic approval by a significant margin, confirming that Moshkevich's distribution was designed before the specific catalyst that produced the current rally. The December 2025 plan similarly predates the approval, establishing its execution parameters before the regulatory outcome was knowable.

Both plans collected the FDA approval rally because both calendars happened to designate this execution window — not because either executive assessed the current price and decided to sell.

The 12-Tier CLO Execution: Plan Precision Across a Range

Rabinowitz's 12-tier execution corridor spanning $266.33 to $278.78 is the most granular plan execution architecture this series has documented — twelve separate price fills across a $12.45 range for a 16,800-share target.

Twelve execution tiers across a single session or adjacent sessions confirms a plan administrator working the block systematically against available intraday depth — the algorithmic execution infrastructure producing multiple fills at incrementally different prices as the stock moved within the session's range. The $12.45 spread across twelve fills reflects natural intraday price variation as the post-FDA-approval momentum created both demand and supply dynamics within the trading window.

The FDA Signatera Companion Diagnostic Approval: The Rally Context

The milestone FDA companion diagnostic approvals for Natera's Signatera platform is the specific regulatory event that produced the vertical rally into which both plans executed — the binary risk reduction that confirms Signatera's clinical utility as a companion diagnostic for specific oncology treatment decisions.

This series documented co-founder Matthew Rabinowitz's March 2026 plan execution at $214.52 in the prior Natera analysis. The current execution range of $266.33 to $278.78 — approximately $52 to $64 above the prior plan's execution level — confirms the Signatera FDA approval has delivered meaningful incremental appreciation to Natera's equity since the co-founder's March plan ran.

Both executives' plans collected the post-approval price appreciation that the March plan could not have anticipated — the calendars executing at whatever the FDA approval rally delivered rather than at any planned price target.

The Combined Retained Position: 296,779 Shares

The 19,800 shares distributed across both executives combined represent a modest aggregate extraction against the 296,779 combined retained direct shares — the two executives maintaining substantial combined personal financial alignment with Natera's Signatera platform following the plan-governed distributions.

At $278.78, the combined 296,779 retained shares represent approximately $82.7 million in combined direct equity exposure — the CLO and Clinical President's ongoing personal commitment to the liquid biopsy platform whose FDA companion diagnostic approval has just validated the specific clinical application that their roles directly oversee.

About Natera, Inc.

Natera, Inc. is a cell-free DNA testing company whose Signatera platform has recently received milestone FDA companion diagnostic approvals, validating its clinical utility for oncology treatment monitoring and response assessment. CLO Daniel Rabinowitz and Clinical Diagnostics President Solomon Moshkevich retain a combined 296,779 direct common shares worth approximately $82.7 million following their independent plan-governed distributions totaling approximately $5,393,141. Natera trades on the Nasdaq under the ticker NTRA.

How to Think About This

The dual-executive same-day cluster scores 88/100 — two independently designed plans executing into the same FDA Signatera approval rally window, producing a same-day combined appearance that generates scanner attention without representing coordinated directional selling.

The December 2025 CLO plan and the November 2024 Clinical President plan are the two analytical anchors — adoption dates that predate the FDA approval and confirm both distributions were designed before the specific catalyst that elevated the execution prices above $266. The 296,779 combined retained shares confirm both executives remain personally and substantially invested in the Signatera platform whose regulatory validation just drove the rally their plans collected.

Two plans. Two adoption dates. One FDA approval. One rally. Both plans collected it simultaneously.

Consolidated Insider Filings